Investors were not impressed with the biotech's latest clinical update.
News & Analysis: BioXcel Therapeutics, Inc.
A Wall Street analyst has high hopes for the company.
Investors were not impressed with the company's latest quarterly update.
The company reported positive results from two pivotal clinical trials.
Here's why investors shouldn't bet on these two companies long-term, at least not yet.
BTAI earnings call for the period ending March 31, 2020.
Clinical trial successes could send shares of these drugmakers screaming higher.
Unlike much of the market, BioXcel Therapeutics is actually up year to date.
See if they can keep climbing.
Shares tumble after the company announces that it is raising capital.